Marbury T - Search Results

1

Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics.

Ankrom W, Yee KL, Sanchez RI, Adedoyin A, Fan L, Marbury T, Preston RA, Iwamoto M, Khalilieh SG. Ankrom W, et al. Among authors: marbury t. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00326-18. doi: 10.1128/AAC.00326-18. Print 2018 Aug. Antimicrob Agents Chemother. 2018. PMID: 29891610 Free PMC article. Clinical Trial.

2

Pharmacokinetics of repaglinide in subjects with renal impairment.

Marbury TC, Ruckle JL, Hatorp V, Andersen MP, Nielsen KK, Huang WC, Strange P. Marbury TC, et al. Clin Pharmacol Ther. 2000 Jan;67(1):7-15. doi: 10.1067/mcp.2000.103973. Clin Pharmacol Ther. 2000. PMID: 10668848 Clinical Trial.

3

Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction.

Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, Sack M, Glue P, Jacobs S, Affrime M. Gupta SK, et al. J Clin Pharmacol. 2002 Oct;42(10):1109-15. doi: 10.1177/009127002401382713. J Clin Pharmacol. 2002. PMID: 12362925 Clinical Trial.

4

Pharmacokinetics and safety of a single oral dose of once-daily alfuzosin, 10 mg, in male subjects with mild to severe renal impairment.

Marbury TC, Blum RA, Rauch C, Pinquier JL. Marbury TC, et al. J Clin Pharmacol. 2002 Dec;42(12):1311-7. doi: 10.1177/0091270002239360. J Clin Pharmacol. 2002. PMID: 12463725 Clinical Trial.

5

Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib.

Gottesdiener K, Agrawal N, Porras A, Wong P, Rogers JD, Gertz BJ, Redfern JS, Marbury T. Gottesdiener K, et al. Among authors: marbury t. Am J Ther. 2003 Jul-Aug;10(4):252-8. doi: 10.1097/00045391-200307000-00004. Am J Ther. 2003. PMID: 12845388 Clinical Trial.

6

Pharmacokinetics of etoricoxib in patients with renal impairment.

Agrawal NG, Matthews CZ, Mazenko RS, Kline WF, Woolf EJ, Porras AG, Geer LA, Wong PH, Cho M, Cote J, Marbury TC, Moncrief JW, Alcorn H Jr, Swan S, Sack MR, Robson RA, Petty KJ, Schwartz JI, Gottesdiener KM. Agrawal NG, et al. J Clin Pharmacol. 2004 Jan;44(1):48-58. doi: 10.1177/0091270003260338. J Clin Pharmacol. 2004. PMID: 14681341

7

Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment.

Zhou XJ, Marbury TC, Alcorn HW, Smith WB, Dubuc Patrick G, Chao GC, Brown NA. Zhou XJ, et al. Antimicrob Agents Chemother. 2006 May;50(5):1721-6. doi: 10.1128/AAC.50.5.1721-1726.2006. Antimicrob Agents Chemother. 2006. PMID: 16641441 Free PMC article. Clinical Trial.

8

Garenoxacin pharmacokinetics in subjects with renal impairment.

Krishna G, Gajjar D, Swan S, Marbury T, Grasela DM, Wang Z. Krishna G, et al. Among authors: marbury t. Curr Med Res Opin. 2007 Mar;23(3):649-57. doi: 10.1185/030079906X167679. Curr Med Res Opin. 2007. PMID: 17355746 Clinical Trial.

9

Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.

Zhou XJ, Swan S, Smith WB, Marbury TC, Dubuc-Patrick G, Chao GC, Brown NA. Zhou XJ, et al. Antimicrob Agents Chemother. 2007 Dec;51(12):4231-5. doi: 10.1128/AAC.00557-07. Epub 2007 Sep 17. Antimicrob Agents Chemother. 2007. PMID: 17875994 Free PMC article. Clinical Trial.

10

Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.

Iwamoto M, Kost JT, Mistry GC, Wenning LA, Breidinger SA, Marbury TC, Stone JA, Gottesdiener KM, Bloomfield DM, Wagner JA. Iwamoto M, et al. Among authors: marbury tc. J Clin Pharmacol. 2008 Jun;48(6):726-33. doi: 10.1177/0091270008318007. Epub 2008 Apr 25. J Clin Pharmacol. 2008. PMID: 18441333 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

196 results

Search Page